Your browser doesn't support javascript.
loading
Controlled release of MT-1207 using a novel gastroretentive bilayer system comprised of hydrophilic and hydrophobic polymers.
Vrettos, Napoleon-Nikolaos; Wang, Peng; Wang, Yuhan; Roberts, Clive J; Xu, Jinyi; Yao, Hong; Zhu, Zheying.
Afiliação
  • Vrettos NN; School of Pharmacy, University of Nottingham, Nottingham, United Kingdom.
  • Wang P; School of Pharmacy, China Pharmaceutical University, Nanjing, P.R. China.
  • Wang Y; School of Pharmacy, University of Nottingham, Nottingham, United Kingdom.
  • Roberts CJ; School of Pharmacy, University of Nottingham, Nottingham, United Kingdom.
  • Xu J; School of Pharmacy, China Pharmaceutical University, Nanjing, P.R. China.
  • Yao H; School of Pharmacy, China Pharmaceutical University, Nanjing, P.R. China.
  • Zhu Z; School of Pharmacy, University of Nottingham, Nottingham, United Kingdom.
Pharm Dev Technol ; 28(8): 724-742, 2023 Oct.
Article em En | MEDLINE | ID: mdl-37493413
ABSTRACT
In the present study, novel gastroretentive bilayer tablets were developed that are promising for the once-a-day oral delivery of the drug candidate MT-1207. The gastroretentive layer consisted of a combination of hydrophilic and hydrophobic polymers, namely polyethylene oxide and Kollidon® SR. A factorial experiment was conducted, and the results revealed a non-effervescent gastroretentive layer that, unlike most gastroretentive layers reported in the literature, was easy to prepare, and provided immediate tablet buoyancy (mean floating lag time of 1.5 s) that lasted over 24 h in fasted state simulated gastric fluid (FaSSGF) pH 1.6, irrespective of the drug layer, thereby allowing a 24-hour sustained release of MT-1207 from the drug layer of the tablets. Furthermore, during in vitro buoyancy testing of the optimised bilayer tablets in media of different pH values (1.0, 3.0, 6.0), the significant difference (one-way ANOVA, p < 0.001) between the respective total floating times indicated that stomach pH effects on tablet buoyancy are important to be considered during the development of non-effervescent gastroretentive formulations and the choice of dosing regimen. To the best of our knowledge, this has not been reported before, and it should probably be factored in when designing dosing regimens. Finally, a pharmacokinetic study in Beagle dogs indicated a successful in vivo 24-hour sustained release of MT-1207 from the optimised gastroretentive bilayer tablet formulations with the drug plasma concentration remaining above the estimated minimum effective concentration of 1 ng/mL at the 24-hour timepoint and also demonstrated the gastroretentive capabilities of the hydrophilic and hydrophobic polymer combination. The optimised formulations will be forwarded to clinical development.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Polímeros Limite: Animals Idioma: En Revista: Pharm Dev Technol Assunto da revista: FARMACIA Ano de publicação: 2023 Tipo de documento: Article País de afiliação: Reino Unido

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Polímeros Limite: Animals Idioma: En Revista: Pharm Dev Technol Assunto da revista: FARMACIA Ano de publicação: 2023 Tipo de documento: Article País de afiliação: Reino Unido
...